Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40569
Title: Abbreviated or Standard Antiplatelet Therapy in HBR Patients Final 15-Month Results of the MASTER-DAPT Trial
Authors: Landi, Antonio
Heg, Dik
Frigoli, Enrico
VRANCKX, Pascal 
Windecker, Stephan
Siegrist, Patrick
Cayla, Guillaume
Wlodalczak, Adrian
Cook, Stephane
Gomez-Blazquez, Ivan
Feld, Yair
Seung-Jung, Park
Mates, Martin
Lotan, Chaim
Gunasekaran, Sengottuvelu
Nanasato, Mamoru
Das , Rajiv
Kelbaek, Henning
Teiger, Emmanuel
Escaned, Javier
Ishibashi, Yuki
Montalescot, Gilles
Matsuo, Hitoshi
Debeljacki, Dragan
Smits, Pieter C.
Valgimigli, Marco
Issue Date: 2023
Publisher: ELSEVIER SCIENCE INC
Source: JACC-Cardiovascular Interventions, 16 (7) , p. 798 -812
Abstract: BACKGROUND Clinical outcomes and treatment selection after completing the randomized phase of modern trials, investigating antiplatelet therapy (APT) after percutaneous coronary intervention (PCI), are unknown. OBJECTIVES The authors sought to investigate cumulative 15-month and 12-to-15-month outcomes after PCI during routine care in the MASTER DAPT trial. METHODS The MASTER DAPT trial randomized 4,579 high bleeding risk patients to abbreviated (n = 2,295) or standard (n = 2,284) APT regimens. Coprimary outcomes were net adverse clinical outcomes (NACE) (all-cause death, myocardial infarction, stroke, and BARC 3 or 5 bleeding); major adverse cardiac and cerebral events (MACCE) (all-cause death, myocardial infarction, and stroke); and BARC type 2, 3, or 5 bleeding. RESULTS At 15 months, prior allocation to a standard APT regimen was associated with greater use of intensified APT; NACE and MACCE did not differ between abbreviated vs standard APT (HR: 0.92 [95% CI: 0.76-1.12]; P = 0.399 and HR: 0.94 [95% CI: 0.76-1.17]; P = 0.579; respectively), as during the routine care period (HR: 0.81 [95% CI: 0.50-1.30]; P = 0.387 and HR: 0.74 [95% CI: 0.43-1.26]; P = 0.268; respectively). BARC 2, 3, or 5 was lower with abbreviated APT at 15 months (HR: 0.68 [95% CI: 0.56-0.83]; P = 0.0001) and did not differ during the routine care period. The treatment effects during routine care were consistent with those observed within 12 months after PCI. CONCLUSIONS At 15 months, NACE and MACCE did not differ in the 2 study groups, whereas the risk of major or clinically relevant nonmajor bleeding remained lower with abbreviated compared with standard APT. (Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen [MASTER DAPT]; NCT03023020) (J Am Coll Cardiol Intv 2023;16:798-812) (c) 2023 by the American College of Cardiology Foundation.
Notes: Valgimigli, M (corresponding author), Ente Osped Cantonale, Cardioctr Ticino Inst, Via Tesserete 48, CH-6900 Lugano, Switzerland.
marco.valgimigli@eoc.ch
Keywords: KEY WORDS antiplatelet therapy;dual antiplatelet therapy;high bleeding risk;percutaneous coronary intervention
Document URI: http://hdl.handle.net/1942/40569
ISSN: 1936-8798
e-ISSN: 1876-7605
DOI: 10.1016/j.jcin.2023.01.366
ISI #: 000996512200001
Category: A1
Type: Journal Contribution
Appears in Collections:Research publications

Files in This Item:
File Description SizeFormat 
Abbreviated or Standard Antiplatelet.pdfPeer-reviewed author version1.39 MBAdobe PDFView/Open
Show full item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.